Cancer Therapies

Positive Prostate Cancer Interim Results Presented in Thalidomide Trials

Published in Cancer Weekly, June 30th, 1997

EntreMed Inc., Rockville, Maryland, and the U.S. National Cancer Institute (NCI), Bethesda, Maryland, announced an increase in the number of prostate cancer patients in NCI-sponsored Phase II clinical trials using thalidomide treatment.

Recent findings showed positive results in Phase II trials using thalidomide in androgen-independent metastatic prostate cancer patients. The first 18 patients treated exhibited prostate-specific antigen (PSA) declines as well as disease stabilization.

These patients have been observed since the onset of trials in early 1996 at the U.S. National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-06-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry